Barclays raised the firm’s price target on Regenxbio to $55 from $45 and keeps an Overweight rating on the shares. The analyst says the company’s new Duchenne muscular dystrophy gene therapy data from the first patient showed high microdystrophin expression despite old age. A single arm pivotal trial could be feasible per FDA feedback, the analyst tells investors in a research note.
Meet Your ETF AI Analyst
- Discover how TipRanks' ETF AI Analyst can help you make smarter investment decisions
- Explore ETFs TipRanks' users love and see what insights the ETF AI Analyst reveals about the ones you follow.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
See today’s best-performing stocks on TipRanks >>
Read More on RGNX:
- Regenxbio price target raised to $39 from $34 at Baird
- Regenxbio’s RGX-202 shows initial efficacy in Duchenne
- REGENXBIO Reports Fourth Quarter and Full Year 2023 Financial Results and Recent Operational Highlights
- Regenxbio expects cash to fund operations into 2H25
- Regenxbio reports Q4 EPS ($1.34), consensus ($1.27)